Navigation Links
Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
Date:1/17/2012

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from the Bayer HealthCare Phase 3 CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial of Bayer's investigational compound regorafenib (BAY 73-4506). The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median OS: 6.4 months vs. 5.0 months for the placebo group) in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after approved standard therapies.[i] This late-breaking abstract, with these updated data, will be presented by Axel Grothey, MD, Professor of Oncology, Mayo Clinic and co-principal investigator of the CORRECT study, in an oral abstract session (LBA No. 385, January 21, 2012 from 2:30 p.m. – 4:00 p.m. PT, Level 3 Ballroom, Moscone Center West) at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.

Additionally, findings from the secondary endpoints of the CORRECT study showed statistically significant improvement in progression-free survival (PFS) (HR=0.49, p<0.000001, median PFS: 1.9 months vs. 1.7 months) and an improvement in disease control rate (44.8% vs. 15.3%) in patients treated with regorafenib compared to those treated with placebo. The difference in objective response rate between the two arms (1.0% vs. 0.4%) did not reach statistical significance.[i]

The most common drug-related treatment-emergent adverse events included fatigue (47.4% vs. 28.1%), hand-foot skin reaction (46.6% vs. 7.5%), diarrhea (33.8% vs. 8.3%), anorexia (30.4% vs. 15.4%), hypertension (27.8% vs. 5.9%), oral mucositis (27.2% vs. 3.6%) and rash/desquamation (26.0% vs. 4.0%) for patients receiving regorafenib
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
4. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
5. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
6. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
7. Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
8. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  AVACEN, Inc. ... a second AVACEN patent covering the medical technology platform supporting ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... The apparatus and methods patent no. 9,066,781 - Methods And ... devices manufactured by AVACEN and specific methods of use, referred ...
(Date:7/1/2015)... July 1, 2015   Continental Clinical Solutions (Continental) announced it is expanding its ... to accommodate increased volume in clinical studies and demand for unique patient populations.  ... ... ... ...
(Date:7/1/2015)... 2015  BioPharmX Corporation (NYSE MKT: BPMX) today announced ... of 3,636,364 shares of its common stock at a ... has granted the underwriters a 30-day option to purchase ... the public offering price. In addition, Korea ... has agreed to purchase 1,081,081 shares of common stock ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 2Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 3Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:7/1/2015)... TX (PRWEB) , ... July 01, 2015 , ... As ... another symptom found in a significant number of women: leg pain. Northeast Houston Vein ... , Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. ...
(Date:7/1/2015)... KY (PRWEB) , ... July 01, 2015 , ... ... Care Transformation Task Force, contributing to newly released white paper: “Pro-actively Identifying the ... paper was published July 1st and is available at: http://www.hcttf.org/resouces-tools . , ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... is helping families get ready for Independence Day celebrations with new takes on ... and versatile options are perfect for any summertime get together. , “Celebrating with ...
(Date:7/1/2015)... York (PRWEB) , ... July 01, 2015 , ... Author Francesca Camp wasn’t ... fell into her lap, so too did her support of the practice; a terrible car ... , In her new book, “Do I Need It ? (And What if I ...
(Date:7/1/2015)... ... July 01, 2015 , ... Who doesn’t want a ... in life with a healthy balance between work and life, and positive friendships and ... new book, Positive Health: Flourishing Lives, Wellbeing in Doctors. , With a focus on ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Boar’s Head Helps Craft a Delicious Independence Day 2Health News:Boar’s Head Helps Craft a Delicious Independence Day 3Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2Health News:Medical Doctor Explains The Healthy Effects of a Positive Outlook in New Book 2
... offer tips to avoid mowing-related hazards , SATURDAY, ... such a common summertime activity that many people forget ... warn. , Each year in the United States, about ... mower-related accidents, according to the U.S. Consumer Product Safety ...
... , WALTHAM, Mass., June 19 I-Therapeutix announced today that ... The round was led by Polaris Venture Partners in ... and SV Life Sciences. , , The ... the United States and to develop sustained drug delivery products ...
... -- As President Obama prepares to sign a bill ... the tobacco industry, a new study from Harvard School ... have continually changed the ingredients and the design of ... exceeded acceptable product variance guidelines. The result, say the ...
... even more toxic than tobacco, , FRIDAY, June 19 (HealthDay ... marijuana is derived, contains compounds that can damage DNA and ... a new study from the United Kingdom. , In ... colleagues found certain carcinogens in cannabis smoke in amounts 50 ...
... guidance asks for less institutional, more personal care , ... environment where residents are free to make choices regarding ... nursing home, according to a guidance issued Friday by ... , The directives in the CMS guidance aim to ...
... DAVIS--"To thine own self be true" may take on ... with plant behavior. Plants engage in self-recognition and ... cuttings planted nearby, says professor Richard Karban of the ... research published in the current edition of Ecology ...
Cached Medicine News:Health News:Don't Get Lazy About Lawn-Mower Safety 2Health News:I-Therapeutix, Inc. Closes $15 Million Financing 2Health News:Study finds that tobacco companies changed design of cigarettes without alerting smokers 2Health News:Make Nursing Homes More Like Home: Medicare 2Health News:Plant communication: Sagebrush engage in self-recognition and warn of danger 2
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint, reaction is complete in five minutes at 37C. Wavelength: 540 nm. Linearity: 1000 mg/dL (11.3 mmol/...
Medicine Products: